Drug Development.

Area of Science:

• Neuroscience
• Pharmacology
• Biomarkers

Background:

• AR1001 (mirodenafil) is an investigational oral phosphodiesterase 5 (PDE5) inhibitor for Alzheimer's disease (AD).
• A phase 2 trial evaluated AR1001's safety and efficacy in mild to moderate AD patients.
• AR1001 demonstrated acceptable safety at 10 mg and 30 mg doses over 26 weeks.

Purpose of the Study:

• To assess the safety and efficacy of AR1001 in patients with mild to moderate AD.
• To evaluate AR1001's impact on cognitive function and AD biomarkers.
• To explore AR1001's potential as a monotherapy for AD.

Main Methods:

• A double-blind, randomized, placebo-controlled trial involving 210 mild to moderate AD patients.
• Participants received daily oral doses of placebo, 10 mg AR1001, or 30 mg AR1001 for 26 weeks.
• Subgroup analyses examined effects based on concomitant AD medication use, focusing on ADAS-Cog-13 and plasma biomarkers (ptau-181, ptau-217).

Main Results:

• While the primary endpoint (ADAS-Cog-13) did not show significant differences overall, the 30 mg AR1001 group showed reduced plasma ptau-181 and ptau-217 compared to placebo.
• In participants not on concomitant AD medication, 30 mg AR1001 monotherapy showed a statistically significant improvement on ADAS-Cog-13 (p=0.012).
• AR1001 30 mg monotherapy also led to significant reductions in plasma ptau-181 (p=0.023) and ptau-217 (p<0.05) compared to placebo.

Conclusions:

• AR1001 (mirodenafil) at 30 mg demonstrated potential as a monotherapy for Alzheimer's disease.
• Subgroup analysis indicated that patients treated with AR1001 30 mg without other AD medications experienced cognitive benefits.
• The study highlights AR1001's potential to modify AD progression by reducing key pathological biomarkers.